Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial

Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial

Background/aims To evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of SB15 versus reference aflibercept (AFL), and switching from AFL to SB15 in neovascular age-related macular degeneration (nAMD).Design Prospective, double-masked, randomised, phase 3 trial.Methods Participants w...

Full description

Bibliographic Details
Main Authors: Se Joon Woo, Srinivas R Sadda, Min Sagong, Cheolmin Yun, Edward Wylegala, Sunil Patel, Miroslav Veith, Jan Ernest, Jan Studnička, Attila Vajas, Inkyung Oh, Mario Bradvica, Michal Orski, Sergei Astakhov, Edit Tóth-Molnár, Adrienne Csutak, Lajos Enyedi, Wooree Choi, Hyerin Jang
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:BMJ Open Ophthalmology
Online Access:https://bmjophth.bmj.com/content/8/1/e001561.full

Internet

https://bmjophth.bmj.com/content/8/1/e001561.full

Similar Items